Last reviewed · How we verify
Methotrexat
At a glance
| Generic name | Methotrexat |
|---|---|
| Sponsor | Biocad |
| Target | Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Acute lymphoid leukemia
- Burkitt's lymphoma
- Carcinoma of female breast
- Crohn's disease
- Erythrodermic psoriasis
- Gestational trophoblastic neoplasia
- Juvenile idiopathic arthritis
- Juvenile rheumatoid arthritis
- Malignant tumor of head and/or neck
- Malignant tumor of lung
- Meningeal Leukemia
- Mycosis fungoides
- Non-Hodgkin's lymphoma
- Osteosarcoma of bone
- Plaque psoriasis
- Psoriasis
- Psoriatic arthritis
- Pustular psoriasis
- Rheumatoid arthritis
Common side effects
- Elevated liver tests
- Nausea/vomiting
- Gastrointestinal reactions
- Ulcerative stomatitis
- Leukopenia
- Nausea
- Abdominal distress
- Stomatitis
- Thrombocytopenia
- Rash/pruritus/dermatitis
- Diarrhea
- Alopecia
Serious adverse events
- Interstitial pneumonitis
- Thromboembolic events
- Aplastic anemia
- Hemorrhagic enteritis
- Intestinal perforation
- Acute hepatitis
- Cirrhosis
- Anaphylaxis
- Vasculitis
- Pericarditis
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (PHASE2)
- A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |